7:50 am Registration & Morning Coffee
Paving the Path to Success With Next Generation Innovations
8:50 am Chair’s Opening Remarks
9:00 am Evolution of Anti-Rejection Strategies for Allogeneic Cell Therapy
9:30 am Next Generation Cancer Immunotherapy: CAR-CIK Manufacturing Process
Synopsis
- Made from allogeneic healthy donor cells
- No leukapheresis required
- No cell purification steps
- Non-viral gene transfer method
10:00 am A Full Landscape Overview of the Allogeneic Cell Therapy Space
Synopsis
- Assessing how allogeneic cell therapies align with the rest of the cell therapy landscape
- What does the existing allogeneic landscape consist of and how has it changed over recent years?
- Insights into potential trends and the potential future of allogeneic therapies for oncology
10:30 am Morning Refreshment Break & Networking
Pre-Clinical & Translation
Supercharging Solid Tumor Targeting for Broader Success
12:00 pm Developing CAR-NK Therapies for Solid Tumors
Synopsis
- We are developing a “combination” CAR-NK therapy (integrating IL15 with anti-CD147 CAR-NK) that has shown a great promise in treating solid tumors in pre-clinical studies
- We have also developed a NK / CAR-NK cell expansion technology platform with great expansion efficiency and fidelity
12:30 pm Development & Production Strategies to Enable Migration from Autologous CAR-T to Allogeneic Gamma/ Delta-T Cells
Synopsis
- Advantages of the gamma/delta-T cell chassis over CAR-T alpha/ beta T-cells
- Native and CAR gamma/delta-T cell killing efficacy in multiple disease applications.
- Discussing the challenges of high-scale, high-quality gamma/ delta-T cell production.
Manufacturing
Driving Scalable Manufacturing & Optimizing Characterization for Successful Commercialisation of Allogenic Therapies
12:00 pm Standards and Strategies for Establishing Fit-For-Purpose Analytical Methods for Cell Therapy Product Characterization
Synopsis
• Update on standards available/under development for cell characterization
• Public-Private partnerships for cell and gene therapy analytical method development
• Description of an approach to establish fit-for-purpose cell viability methods that are relevant to a cell manufacturing process
12:30 pm Characterizing Raw Starting Materials & Product for Quality, Safety & Efficacy
Supply/Storage
Revolutionizing Data Management & Process Integration
12:00 pm Innovating Sophisticated Digital Tools to Establish a Data Management/ Integration System Equipped to Handle Complex Allogeneic Products
Synopsis
- As next generation allogeneic products become more complex, how can we develop tools to manage more data and processing volumes?
- Digitalising the supply chain for greater control and tracking of raw material source, supply and quality
12:30 pm Cell Therapy Lab / Cell Pharmacy : The Resources Needed for the Onboarding of Cell Therapy Products
Synopsis
- The field currently
- Staff, Space, and the Challenge of New Products
- Standardization – Where do we begin?
1:00 pm Lunch
Ushering in the Next Wave of Universal Cell Therapy – Future Directions
2:00 pm Unlocking the Groundbreaking Potential of iNKT Cells for Allogeneic Cancer Therapy
Synopsis
- Arovella is developing its novel iNKT cell therapy platform to develop allogenic cell therapies to treat cancer.
- Arovella is initially targeting haematological malignancies with its lead product ALA-101. Through a strategic collaboration with Imugene, Arovella will use ALA-101 to target solid tumours.
- Arovella is also developing its DKK1- CARiNKT cells to target multiple myeloma and solid tumours.
2:30 pm Developing Next-Generation Allogeneic Therapies for Solid Tumors Based on Gamma Delta T cells
Synopsis
- Discussing characteristics of gamma delta T cells as source for an allogeneic cell therapy approach
- Redirecting gamma delta T cells with TCRs against peptide-HLA targets to combat solid tumors
- Exploring next-gen strategies to potentiate anti-tumor activity
3:00 pm Afternoon Break & Refreshments
3:30 pm Development of iPSC-Derived Gamma Delta T Cell Therapies for Treatment of Liquid & Solid Tumors
Synopsis
- Harnessing the power of induced pluripotent stem cells (iPSCs) to develop novel allogeneic CAR-T cell therapies for cancer
- Multiplex engineering of iPSCs to develop allogeneic Gamma Delta T cells that can safely and effectively mediate anti-tumor immunity
- CAR design strategies that address disease-specific challenges
4:00 pm B Cells as a Novel Off-The-Shelf Cell Therapy
Synopsis
- CRISPR/Cas gene editing results in high efficiency B cell engineering
- B cells can be differentiated into long lived plasma cells
- Plasma cells have naturally allogeneic properties that make them ideal for cell therapy
4:30 pm SEAKERs: Targeted Cellular Micropharmacies that Generate Small- Molecule Drugs in situ
Synopsis
- SEAKER (Synthetic Enzyme Armed KillER) cells are CAR-T cells engineered to activate small-molecule prodrugs locally at tumor sites
- SEAKER platform is modular and can incorporate different engineered cells, antigen targets, and enzyme–prodrug combinations in vitro and in vivo proofof- concept has been established for the SEAKER approach using two different enzyme–prodrug combinations